

PERSONAL INFORMATION

Alessia Beccacece

PROFESSIONAL EXPERIENCE

 From August 2023 **Health Care Researcher**

Scientific Direction, National Institute of Health and Science of Aging, IRCCS INRCA, Ancona, Italy

- Epidemiological and translational research on aging and polypharmacotherapy in older adults

 April 2023 – July 2023 **Health Care Research Assistant**

Scientific Direction, National Institute of Health and Science of Aging, IRCCS INRCA, Ancona, Italy

- Support to the research activities

 February 2021 – March 2023 **Clinical Research Coordinator**

UOC High Intensity Infectious Diseases, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy

- Project management, coordination of clinical trials and observational studies, protocols and informed consents drafting, study submission to the Ethics Committee/Regulatory Authority, data management in databases/eCRFs, participation in working groups for the research of repurposing drugs in emerging infectious diseases, medical writing.

 January 2020 – February 2020 **Intern at Clinical Trial Center**

Clinical Research Unit and Clinical Competence, Sapienza Ethics Committee, Policlinico Umberto I, Rome, IT

- Completeness check and review of clinical trial documentation submitted for Ethics Committee approval

 February 2014 – December 2020 **Pharmacist**

July 2019 – December 2020: Farmacia Ratti, Castelfidardo (AN), Italy

February 2014 – Jun 2019: Farmacia Ville, Falconara Marittima (AN), Italy

- Medicinal products dispensation, prescription control, phytotherapy area management

 February 2013 – July 2013 **Intern in Preclinical Research**

Centre for Behaviour and Neurosciences of the University of Groningen, The Netherlands

- Practice in the animal facility, biological sample collection, laboratory analysis

EDUCATION AND TRAINING

 From August 2022 **Clinical Pharmacology and Toxicology Resident**

Sapienza University of Rome, Italy

 November 2022 **Professional license to practice as a Senior Chemist**

University of Camerino, Italy

 May 2020 **Second Level Professional Master program in Clinical Research: Methodology, Pharmacovigilance, Legal and Regulatory Affairs**

Sapienza University of Rome, Italy

Final mark 110/110 and Laude

 December 2013 **Professional license to practice as Pharmacist**

University of Camerino, Italy

 October 2013 **Master's Degree in Pharmacy**

University of Camerino, Italy

Final mark 110/110 with honors

SCIENTIFIC PRODUCTION

1. Vita S, Fortiano D, De Luca A, **Beccacece A**, Marchioni L, Nicastrì E, On Behalf Of The Covid-Inmi Study Group. *Drug Policies Skyline during COVID-19 Pandemic*. J Clin Med. 2021 Jul 15;10(14):3117.
2. Sacchi A, Grassi G, Notari S, Gili S, Bordoni V, Tartaglia E, Casetti R, Cimini E, Mariotti D, Garotto G, **Beccacece A**, Marchioni L, Bibas M, Nicastrì E, Ippolito G, Agrati C. *Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection*. Cells. 2021 Aug 17;10(8):2111.
3. Cimini E, Grassi G, **Beccacece A**, Casetti R, Castilletti C, Capobianchi MR, Nicastrì E, Agrati C. *In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFN γ Production by Circulating V δ 2 T Cells*. Viruses. 2022 Jan 12;14(1):130.
4. D'Abramo A, Vita S, Maffongelli G, **Beccacece A**, Agrati C, Cimini E, Colavita F, Giancola ML, Cavasio A, Nicastrì E; Spallanzani COVID-19 Case Investigation Team. *Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway*. Front Immunol. 2022 May 27;13:911339.
5. Nobile F, Michelozzi P, Ancona C, Cappai G, Cesaroni G, Davoli M, Di Martino M, Nicastrì E, Girardi E, **Beccacece A**, Scognamiglio P, Sorge C, Vairo F, Stafoggia M. *Air pollution, SARS-CoV-2 incidence and COVID-19 mortality in Rome - a longitudinal study*. Eur Respir J. 2022 Jul 26;60(3):2200589.
6. Vita S, Rosati S, Ascoli Bartoli T, **Beccacece A**, D'Abramo A, Mariano A, Scorzoloni L, Goletti D, Nicastrì E. *Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature*. Pathogens. 2022 Aug 5;11(8):882.
7. Aiello A, Coppola A, Vanini V, Petrone L, Cuzzi G, Salmi A, Altera AMG, Tortorella C, Gualano G, Gasperini C, Scolieri P, **Beccacece A**, Vita S, Bruzzese V, Lorenzetti R, Palmieri F, Nicastrì E, Goletti D. *Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon- γ release assay*. Int J Infect Dis. 2022 Sep;122:841-849. Epub 2022 Jul 22.
8. Giancola ML, Corpolongo A, Comandini UV, Del Nonno F, Montalbano M, Petrone A, Carrara S, Mariano A, **Beccacece A**, Maffongelli G, Nicastrì E. *Severe drug-induced liver injury (DILI) associated with benzimidazole therapy for Chagas' disease*. J Antimicrob Chemother. 2022 Nov 28;77(12):3515-3517.
9. **Beccacece A**, Ascoli Bartoli T, Nicastrì E. *Re: Remdesivir for the treatment of COVID-19 by Lee et al*. Clin Microbiol Infect. 2023 Jan;29(1):114. Epub 2022 Oct 4.
10. Ciccocanti F, Antonioli M, Sacchi A, Notari S, Farina A, **Beccacece A**, Fusto M, Vergori A, D'Offizi G, Taglietti F, Antinori A, Nicastrì E, Marchioni L, Palmieri F, Ippolito G, Piacentini M, Agrati C, Fimia GM. *Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation*. Clin Proteomics. 2022 Nov 8;19(1):38.
11. Mastrorosa I, Gagliardini R, Segala F, Mondì A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, camici M, Mosti S, Bini T, Maffongelli G, **Beccacece A**, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastrì E, D'Arminio Monforte A, Palmieri F, Cingolani, Vaia F, Antinori A, ESCAPE study group. *Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study*. eClinicalMedicine. 202357: 101895
12. Zavaroni S, Tristano I, Casamenti V, Colonna V, Cereti M, Mamone M, Prencipe U, Sanzone F, Murgia M, Masala S, **Beccacece A**, Vetrano M, Vulpiani MC, Bemporad J. *Ultrasound-based Neuropathy Diagnosis in COVID-19 Patients in Post-intensive Care Rehabilitation Settings: A Retrospective Observational Study*. Arch Phys Med Rehabil. 2023 Feb 26:S0003-9993(23)00101-6.
13. Tempestilli M, Mondì A, Matusali G, Mariotti D, Pinnetti C, **Beccacece A**, Cimini E, Mazzotta V, Carletti F, Faccendini P, Maggi F, Girardi E, Nicastrì E, Vaia F, Antinori A. *Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpox*. Lancet Infect Dis. 2023 Mar 30:S1473-3099(23)00214-1.
14. Mondì A, Mastrorosa I, Piselli P, Cimaglia C, Matusali G, Carletti F, Giannico G, Milozzi E, Biliotti E, Di Bari S, Chinello P, **Beccacece A**, Faraglia F, Vittozzi P, Mosti S, Tetaj N, Stazi GV, Pinnetti C, Camici M, D'Annunzio A, Marani A, Fabeni L, Specchiarello E, Gruber CEM, Villanacci A, Minicucci S, Garbuglia AR, Ianniello S, Marchioni L, Taglietti F, D'Offizi G, Palmieri F, Nicastrì E, Maggi F, Vaia F, Girardi E, Antinori A. *Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes*. J Med Virol. 2023 Jun;95(6):e28831.
15. Mazzotta V, Cozzi-Lepri A, Lanini S, Mondì A, Carletti F, Tavelli A, Gagliardini R, Vita S, Pinnetti C, Aguglia C, Colavita F, Faccendini P, Matusali G, Faraglia F, **Beccacece A**, Paulicelli J, Girardi E, Nicastrì E, Vaia F, Maggi F, Antinori A. *Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox*. J Med Virol. 2023 Jun;95(6):e28868.
16. Pasquini Z, Toschi A, Casadei B, Pellegrini C, D'Abramo A, Vita S, **Beccacece A**, Bussini L, Chionsini MC, Dentale N, Cantiani A, Lazzarotto T, Bartoletti M, Nicastrì E, Zinzani P, Giannella M, Viale P. *Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection*. Hematol Oncol. 2023 Jul 15. doi: 10.1002/hon.3206 PMID: 37452579.

PRESENTATIONS AT NATIONAL CONGRESSES

1. **Beccacece A**, Vita S, Navarra A, Pennacchiotti C, Maffongelli G, Ascoli Bartoli T, Curtolo A, Mazzotta S, D'Offizi G, Palmieri F, Marchioni L, Taglietti F, Faccendini P, Antinori A, Vaia F, Girardi E, Nicastrì E. *Trend prescrittivo di farmaci off-label e unlicensed nella gestione di pazienti ospedalizzati con infezione da SARS-CoV-2 in un centro clinico italiano*. Oral Presentation, XXI Congresso SIMIT, Roma, 20-23 Nov 2022

Rome, 27/10/2023